Pediatric suspension formulation
The present disclosure relates to storage-stable proton pump inhibitor (PPI) systems comprising a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, which are constituted with water prior to administration. The present disclosure also relates to oral pharmaceutical suspensions comprising water, a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, and one or more buffering agents.
1 . A storage-stable omeprazole system, the system comprising (i) a first mixture comprising (a) a therapeutically effective amount of omeprazole, or a pharmaceutically acceptable salt thereof, (b) optionally a first desiccant, and (c) optionally a first buffering agent, wherein the first mixture contains a percentage of moisture of no more than about 2.5%; and (ii) a second mixture comprising a second buffering agent, wherein the second mixture contains a percentage of moisture of no more than about 2.5%, wherein the first mixture and the second mixture are stored separately from each other and are mixed together on or just before constitution with water, and wherein the system contains no sodium from a sodium-containing buffering agent or the system contains sodium and potassium at a ratio of from about 1:2.6 to about 1:3.4 by weight.
2 . The storage-stable omeprazole system of claim 1 , wherein the sodium and potassium are present at a ratio of about 1:3.2 by weight.
3 . The storage-stable omeprazole system of claim 1 , wherein the first mixture and/or the second mixture has a moisture content of about 0.5% to about 1.5%.
4 . The storage-stable omeprazole system of claim 1 , wherein the first mixture comprises (b) a first desiccant and/or the second mixture further comprises a second desiccant.
5 . The storage-stable omeprazole system of claim 1 , wherein the first mixture further comprises (c) a first buffering agent.
6 . The storage-stable omeprazole system of claim 1 , wherein the first mixture and the second mixture are each independently in a form of a powder, a pellet, a granule, a seed, a bead, a spheroid, a microsphere, or a mixture thereof.
7 . The storage-stable omeprazole system of claim 1 , wherein the omeprazole or the pharmaceutically acceptable salt thereof is micronized.
8 . The storage-stable omeprazole system of claim 1 , wherein the omeprazole or the pharmaceutically acceptable salt thereof is a mixture of micronized and non-micronized omeprazole or the pharmaceutically acceptable salt thereof.
9 . The storage-stable omeprazole system of claim 5 , wherein the first buffering agent and the second buffering agent together provide a buffering capacity of about 2 mEq/ml dose of constituted powder with water.
10 . The storage-stable omeprazole system of claim 9 , wherein the first buffering agent and the second buffering agent are each independently selected from the group consisting of alkali metal or alkaline earth metal carbonates, bicarbonates, phosphates, citrates, borates, acetates, phthalates, tartrates, succinates, and mixtures thereof.
11 . The storage-stable omeprazole system of claim 10 , wherein the first buffering agent and the second buffering agent are each independently selected from the group consisting of sodium bicarbonate, potassium bicarbonate, and a mixture thereof.
12 . The storage-stable omeprazole system of claim 11 , wherein the first buffering agent is sodium bicarbonate.
13 . The storage-stable omeprazole system of claim 11 , wherein the second buffering agent is a mixture of sodium bicarbonate and potassium bicarbonate.
14 . The storage-stable omeprazole system of claim 11 , wherein the first mixture and the second mixture together comprise sodium bicarbonate and potassium bicarbonate at a ratio of about 1:2.7 by weight.
15 . The storage-stable omeprazole system of claim 11 , wherein the first buffering agent and the second buffering agent are potassium bicarbonate.
16 . The storage-stable omeprazole system of claim 15 , wherein the storage-stable omeprazole system is provided in a drug delivery device suitable for multi-dose administration of omeprazole, or the pharmaceutically acceptable salt thereof.
17 . The storage-stable omeprazole system of claim 16 , wherein the drug delivery device comprises two chambers.
18 . The storage-stable omeprazole system of claim 17 , wherein the drug delivery device further comprises a means for releasing the contents of the first chamber into the second chamber without removing the cap from the drug delivery device.
19 . The storage-stable omeprazole system of claim 16 , wherein the storage-stable omeprazole system is provided in a container body comprising a cap, wherein (i) the container body contains the second mixture and has a container opening formed in an upper end thereof; (ii) the cap comprises a cylindrical accommodation portion comprising the first mixture and a cap portion sealing an upper end of the accommodation portion, and wherein (iii) the cap is mounted in the container opening of the container body, wherein when the cap is twisted, the first mixture is released into the container body.
20 . The storage-stable omeprazole system of claim 1 , wherein the omeprazole system remains stable at 25° C./60% relative humidity for at least 2 years.
21 . An oral pharmaceutical suspension, comprising water and a pharmaceutically effective amount of a storage-stable omeprazole system of claim 1 , dispersed in the water, and wherein the suspension contains no sodium from a sodium-containing buffering agent or the suspension contains sodium and potassium at a ratio of from about 1:2.6 to about 1:3.4 by weight.
22 . The oral pharmaceutical suspension of claim 21 , wherein about 1 ml of the suspension contains from about 1 mg to about 10 mg of omeprazole, or the pharmaceutically acceptable salt thereof.
23 . The oral pharmaceutical suspension of claim 22 , wherein about 1 ml of the suspension contains about 2 mg or about 4 mg of omeprazole, or the pharmaceutically acceptable salt thereof.
24 . The oral pharmaceutical suspension of claim 21 , wherein the first and second buffering agents together provide a buffering capacity of about 2 mEq per ml of the suspension.
25 . The oral pharmaceutical suspension of claim 21 , wherein the suspension is provided in a drug delivery device suitable for multi-dose administration of omeprazole.
26 . A method of inhibiting gastric acid secretion, comprising administering to a subject in need thereof an effective amount of the oral pharmaceutical suspension of claim 21 .
27 . The method of claim 26 , wherein the subject is a child.
28 . A method of preparing an oral pharmaceutical suspension, comprising combining (i) a first mixture comprising (a) a therapeutically effective amount of omeprazole, or a pharmaceutically acceptable salt thereof, (b) optionally a first desiccant, and (c) optionally a first buffering agent, wherein the first mixture contains a percentage of moisture of no more than about 2.5%; with (ii) a second mixture comprising a second buffering agent, wherein the second mixture contains a percentage of moisture of no more than about 2.5%; to obtain a combined mixture, wherein the combined mixture contains no sodium from a sodium-containing buffering agent or the combined mixture contains sodium and potassium at a ratio of from about 1:2.6 to about 1:3.4 by weight; and adding water to the combined mixture.
29 . A method of inhibiting gastric acid secretion, comprising administering to a subject in need thereof an effective amount of an oral pharmaceutical suspension comprising water, a pharmaceutically effective amount of omeprazole, or a pharmaceutically acceptable salt thereof, dispersed in the water, and one or more buffering agents, wherein the suspension contains no sodium from a sodium-containing buffering agent or the suspension contains sodium and potassium at a ratio of from about 1:2.6 to about 1:3.4 by weight; and
wherein the oral pharmaceutical suspension is prepared as claimed in claim 28 .
30 . The oral pharmaceutical suspension of claim 21 , wherein the suspension remains stable for at least one month at 2° C.-8° C. after constitution with water.
31 . A method of administering an oral pharmaceutical suspension to a subject in need of inhibition of gastric acid secretion, said method comprising 1) preparing an oral pharmaceutical suspension, comprising combining (i) a first mixture comprising (a) a therapeutically effective amount of omeprazole, or a pharmaceutically acceptable salt thereof, (b) optionally a first desiccant, and (c) optionally a first buffering agent, wherein the first mixture contains a percentage of moisture of no more than about 2.5%; with (ii) a second mixture comprising a second buffering agent, wherein the second mixture contains a percentage of moisture of no more than about 2.5%; to obtain a combined mixture, wherein the combined mixture contains no sodium from a sodium-containing buffering agent or the combined mixture contains sodium and potassium at a ratio of from about 1:2.6 to about 1:3.4 by weight; and adding water to the combined mixture; and 2) administering to the subject in need thereof an effective amount of the oral pharmaceutical suspension.
32 . The method of claim 31 , wherein the subject is a child.